Lenvatinib improves anti-PD-1 therapeutic efficacy by promoting vascular normalization via the NRP-1-PDGFRβ complex in hepatocellular carcinoma

INTRODUCTION: The limited response to immune checkpoint blockades (ICBs) in patients with hepatocellular carcinoma (HCC) highlights the urgent need for broadening the scope of current immunotherapy approaches. Lenvatinib has been shown a potential synergistic effect with ICBs. This study investigate...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Jieying, Guo, Zhixing, Song, Mengjia, Pan, Qiuzhong, Zhao, Jingjing, Huang, Yue, Han, Yulong, Ouyang, Dijun, Yang, Chaopin, Chen, Hao, Di, Muping, Tang, Yan, Zhu, Qian, Wang, Qijing, Li, Yongqiang, He, Jia, Weng, Desheng, Xiang, Tong, Xia, JianChuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10400764/
https://www.ncbi.nlm.nih.gov/pubmed/37545530
http://dx.doi.org/10.3389/fimmu.2023.1212577

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10400764/
https://www.ncbi.nlm.nih.gov/pubmed/37545530
http://dx.doi.org/10.3389/fimmu.2023.1212577

Ejemplares similares